Joint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, The First Hospital of Jilin University, Changchun 130021, P. R. China.
State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, P. R. China.
Theranostics. 2023 Sep 25;13(15):5266-5289. doi: 10.7150/thno.81650. eCollection 2023.
Immunoadjuvants, as an indispensable component of tumor vaccines, can observably enhance the magnitude, breadth, and durability of antitumor immunity. However, current immunoadjuvants suffer from different issues such as weak immunogenicity, inadequate cellular internalization, poor circulation time, and mono-functional bioactivity. Herein, we construct Fe-Shikonin metal-phenolic networks (FeShik) nanomedicines as immunogenic cell death (ICD) stimulants and multifunctional immunoadjuvants for tumor vaccination. The multifunctionality of FeShik nanomedicines is investigated by loading ovalbumin (OVA) as the model antigen to construct OVA@FeShik nanovaccines or 4T1 tumor cell fragment (TF) as homologous antigen to construct TF@FeShik nanovaccines. In vitro examinations including GSH responsive, •OH generation, colloid stability, cellular uptake, cytotoxicity mechanism of ferroptosis and necroptosis, ICD effect, the promotion of DC maturation and antigen cross-presentation were studied. In vivo observations including pharmacokinetics and biodistribution, antitumor effect, abscopal effect, immune memory effect, and biosafety were performed. The presence of FeShik nanomedicines can significantly prolong the blood circulation time of antigens, increasing the bioavailability of antigens. Upon phagocytosis by tumor cells, FeShik nanomedicines can disassemble into Fe and Shikonin in response to tumor microenvironments, leading to ICD of tumor cells via ferroptosis and necroptosis. Consequently, ICD-released autologous tumor cell lysates and pro-inflammatory cytokines not only stimulate DC maturation and antigen cross-presentation, but also promote macrophage repolarization and cytotoxic T lymphocyte infiltration, resulting in the activation of adaptive immune responses toward solid tumors. In a word, our FeShik supramolecular nanomedicines integrate bioactivities of ICD stimulants and immunoadjuvants, such as eradicating tumor cells, activating antitumor immune responses, modulating immunosuppressive tumor microenvironments, and biodegradation after immunotherapy. Encouraged by the diversity of polyphenols and metal ions, our research may provide a valuable paradigm to establish a large library for tumor vaccination.
免疫佐剂作为肿瘤疫苗不可或缺的组成部分,可以显著增强抗肿瘤免疫的强度、广度和持久性。然而,目前的免疫佐剂存在免疫原性弱、细胞内化不足、循环时间短、生物活性单一等问题。在此,我们构建了负载卵清蛋白(OVA)的 Fe-Shikonin 金属多酚网络(FeShik)纳米药物作为免疫原性细胞死亡(ICD)刺激剂和多功能免疫佐剂用于肿瘤疫苗接种。通过装载 OVA 作为模型抗原构建 OVA@FeShik 纳米疫苗,或装载同源抗原 4T1 肿瘤细胞碎片(TF)构建 TF@FeShik 纳米疫苗,研究了 FeShik 纳米药物的多功能性。进行了体外研究,包括 GSH 响应、•OH 生成、胶体稳定性、细胞摄取、铁死亡和坏死性细胞死亡的细胞毒性机制、ICD 效应、DC 成熟和抗原交叉呈递的促进作用。进行了体内观察,包括药代动力学和生物分布、抗肿瘤作用、远隔效应、免疫记忆效应和生物安全性。FeShik 纳米药物的存在可以显著延长抗原的血液循环时间,提高抗原的生物利用度。当被肿瘤细胞吞噬后,FeShik 纳米药物可以响应肿瘤微环境分解为 Fe 和 Shikonin,通过铁死亡和坏死性细胞死亡导致肿瘤细胞发生 ICD。因此,ICD 释放的自体肿瘤细胞裂解物和促炎细胞因子不仅刺激 DC 成熟和抗原交叉呈递,还促进巨噬细胞重极化和细胞毒性 T 淋巴细胞浸润,从而激活针对实体肿瘤的适应性免疫反应。总之,我们的 FeShik 超分子纳米药物整合了 ICD 刺激剂和免疫佐剂的生物活性,如消除肿瘤细胞、激活抗肿瘤免疫反应、调节免疫抑制性肿瘤微环境以及免疫治疗后的生物降解。受多酚和金属离子多样性的启发,我们的研究可能为建立用于肿瘤疫苗接种的大型化合物库提供了有价值的范例。
ACS Appl Mater Interfaces. 2022-8-24
Acc Chem Res. 2024-3-19
Acc Chem Res. 2020-9-15
Acc Chem Res. 2020-12-15
Drug Discov Today. 2024-3
Int J Nanomedicine. 2024-12-19
Front Pharmacol. 2024-10-11
Front Immunol. 2024
Front Pharmacol. 2024-5-9
Chem Soc Rev. 2022-5-23